PremiumRatingsBeam Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating Beam Therapeutics: Promising Growth Prospects and Strategic Advancements Support Buy Rating Beam Therapeutics price target lowered to $25 from $31 at Barclays PremiumThe FlyCathie Wood’s ARK Investment buys 135K shares of Beam Therapeutics today Beam Therapeutics’ BEAM-302: Promising Clinical Data and Market Potential Drive Buy Rating Beam Therapeutics presents additional data for BEAM-302 in AATD PremiumThe FlyBeam Therapeutics upgraded to Buy from Neutral at BofA Beam announces FDA clearance of BEAM-302 investigational new drug application Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today 
